Medicare drug coverage

Basaglar: 2027 Medicare Part D coverage

38 of 5,495 Part D plans (1%) list Basaglar on their 2027 formulary, the plan's list of covered drugs (the same share as 2026). 55% of those require prior authorization, step therapy, or a quantity limit. Plan counts include both Medicare Advantage plans with drug coverage (5,172 MA-PD) and stand-alone drug plans (323 PDP).

License: a US government work, in the public domain (Public Domain Mark 1.0).

Data only, not plan advice. Confirm on Medicare.gov Plan Finder or 1-800-MEDICARE.

2027 compared with 2026

Basaglar is number 72 by total Medicare Part D spending in 2024 ($665 million). Plans that list it most often put it on tier 4 (a tier is the cost level a plan puts a drug on; a lower tier usually costs less). Counts use 3 RxNorm products for this name.

Basaglar Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it49 (1%)38 (1%)no change
Prior authorization (of plans that list it)8 (16%)7 (18%)+2 points
Step therapy (of plans that list it)15 (31%)14 (37%)+6 points
Quantity limit (of plans that list it)0 (0%)0 (0%)no change
Any of the three (of plans that list it)23 (47%)21 (55%)+8 points
Not listed or restricted (of all plans)5,492 (100%)5,478 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

For pharmacies and agencies: check a whole drug list against 2027 formularies.

Upload your patient list or your book of clients and Rivvi checks each drug against the CMS 2027 formulary files, plan by plan, so you see tier changes and new limits before the next refill or open enrollment. Free to start. HIPAA BAA included.

For pharmaciesFor agencies

Formulary tier

Basaglar formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 12 (4%)0 (0%)
Tier 324 (49%)16 (42%)
Tier 423 (47%)21 (55%)
Tier 60 (0%)1 (3%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan IDs are in both files. 0 of them (0%) added prior authorization, step therapy, or a quantity limit for Basaglar, and 2 stopped listing it.

Basaglar: plans in both 2026 and 2027
Plan by planPlans
Same plan ID in both years4,380
Listed it in 2026, not in 20272 (0%)
Listed it in 2027, not in 20260 (0%)
Moved it to a higher tier1 (0%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit0 (0%)
Added at least one of the three0 (0%)
Removed at least one of the three0 (0%)
Plan IDs new in 20271,115
2026 plan IDs not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave Basaglar off the formulary or list it with prior authorization, step therapy, or a quantity limit. 47 states tie for the highest share, 100%; New Jersey ranks last at 97%. States at the same share are ordered by the prior authorization or step therapy share; states equal on both shares share a rank, marked Tied.

States from most to least restrictive for Basaglar, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Wisconsin97100%7%no change
Tied 2Alaska9100%0%no change
Tied 2Alabama115100%0%no change
Tied 2Arkansas86100%0%no change
Tied 2Arizona148100%0%no change
Tied 2California397100%0%no change
Tied 2Colorado106100%0%no change
Tied 2Connecticut54100%0%no change
Tied 2District of Columbia21100%0%no change
Tied 2Delaware43100%0%no change
Tied 2Georgia151100%0%no change
Tied 2Hawaii50100%0%no change
Tied 2Iowa64100%0%no change
Tied 2Idaho45100%0%no change
Tied 2Illinois133100%0%no change
Tied 2Indiana140100%0%no change
Tied 2Kansas84100%0%no change
Tied 2Kentucky123100%0%no change
Tied 2Louisiana126100%0%no change
Tied 2Massachusetts92100%0%+2 points
Tied 2Maryland49100%0%no change
Tied 2Maine52100%0%no change
Tied 2Michigan183100%0%no change
Tied 2Minnesota63100%0%no change
Tied 2Missouri171100%0%no change
Tied 2Mississippi105100%0%no change
Tied 2Montana27100%0%no change
Tied 2North Carolina177100%0%no change
Tied 2North Dakota26100%0%no change
Tied 2Nebraska51100%0%no change
Tied 2New Hampshire25100%0%no change
Tied 2New Mexico68100%0%no change
Tied 2Nevada100100%0%no change
Tied 2New York215100%0%no change
Tied 2Ohio173100%0%no change
Tied 2Oklahoma81100%0%no change
Tied 2Rhode Island29100%0%no change
Tied 2South Carolina91100%0%no change
Tied 2South Dakota30100%0%no change
Tied 2Tennessee157100%0%no change
Tied 2Texas412100%0%no change
Tied 2Utah53100%0%no change
Tied 2Virginia145100%0%no change
Tied 2Vermont14100%0%no change
Tied 2Washington114100%0%no change
Tied 2West Virginia70100%0%no change
Tied 2Wyoming13100%0%no change
Tied 48Oregon9299%0%no change
Tied 48Florida54999%0%+1 point
50Pennsylvania32498%4%+1 point
51New Jersey7497%3%+2 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave Basaglar off or restrict it.

Basaglar coverage by parent organization, 2027
Parent organization2027 plans ↑List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
CareFirst, Inc.50%none list it100%no change0
General Catalyst Group Management Holdings LP50%none list it100%new in 20270
Harris County Hospital District50%none list it100%no change0
Independent Living Systems, LLC50%none list it100%no change0
Mass General Brigham Incorporated50%none list it100%no change0
PacificSource50%none list it100%no change0
SNP Holdings, LLC50%none list it100%no change0
USAble Mutual Insurance Company50%none list it100%no change0
Baystate Health, Inc.60%none list it100%no change0
Blue Cross Blue Shield of Arizona60%none list it100%no change0
Blue Cross Blue Shield of Kansas60%none list it100%no change0
BlueCross BlueShield of South Carolina (BCBSSC)60%none list it100%no change0
CareSource60%none list it100%+29 points0
Clever Care Health Plan, Inc.60%none list it100%no change0
Eternal Health of Delaware, Inc.60%none list it100%no change0
Hawaii Medical Service Association60%none list it100%no change0
Health First Shared Services, Inc.6100%0%0%no change0
Independent Health Association, Inc.60%none list it100%no change0
LifeBridge Health, Inc.60%none list it100%no change0
The Health Plan of West Virginia, Inc.60%none list it100%no change0
UNICO Services, Inc.60%none list it100%no change0
Verda Healthcare, Inc.60%none list it100%no change0
Allina Health and Aetna Insurance Holding Company70%none list it100%no change0
Baylor Scott & White Health70%none list it100%no change0
Blue Cross and Blue Shield of Massachusetts, Inc.70%none list it100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Other Insulin Glargine,Hum.Rec.Anlog products

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing